Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia

Summary

The main objective of this study is to compare microglia activation as measured with proton Magnetic Resonance Spectroscopy (1H-MRS) between recent-onset schizophrenia patients who are randomised to CBD and those randomised to placebo.

Timeline

Start

2017-11-03

Primary completion

2020-01-31

Completion

2020-01-31

Drugs

Indications